{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:01:04Z","timestamp":1792004464878,"version":"4.4.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Takeda Pharma Vertrieb GmbH & Co. KG, Germany"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-04022-7","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T07:31:23Z","timestamp":1749195083000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Treatment sequences, outcomes, healthcare utilization, and costs in patients with inflammatory bowel diseases requiring advanced treatment\u2014real world comparative effectiveness from German claims data"],"prefix":"10.1186","volume":"25","author":[{"given":"Axel","family":"Dignass","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Teich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"S\u00fcnwoldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"D\u00fcnweber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Weinhold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Borchert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Kudernatsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"key":"4022_CR1","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2017","unstructured":"Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390:2769\u201378. https:\/\/doi.org\/10.1016\/S0140-6736(17)32448-0.","journal-title":"Lancet"},{"issue":"8","key":"4022_CR2","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1055\/a-2060-0935","volume":"61","author":"T Kucharzik","year":"2023","unstructured":"Kucharzik T, Dignass A, Atreya R, Bokemeyer B, Esters P, Herrlinger K, et al. Aktualisierte S3-Leitlinie Colitis ulcerosa (Version 6.1): Februar 2023 \u2013 AWMF-Registriernummer: 021\u2013009. Z Gastroenterol. 2023;61(8):1046\u2013134.","journal-title":"Z Gastroenterol"},{"key":"4022_CR3","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1055\/a-1713-3941","volume":"60","author":"A Sturm","year":"2022","unstructured":"Sturm A, Atreya R, Bettenworth D, Bokemeyer B, Digna\u00df A, Ehehalt R, et al. Aktualisierte S3-Leitlinie \u201eDiagnostik und Therapie des Morbus Crohn\u201c der Deutschen Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) \u2013 August 2021 \u2013 AWMF-Registernummer: 021\u2013004. Zeitschrift fur Gastroenterologie. 2022;60:332\u2013418. https:\/\/doi.org\/10.1055\/a-1713-3941.","journal-title":"Zeitschrift fur Gastroenterologie."},{"issue":"05","key":"4022_CR4","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1055\/a-2271-0994","volume":"62","author":"T Kucharzik","year":"2024","unstructured":"Kucharzik T, Dignass A, Atreya R, Bokemeyer B, Esters P, Herrlinger K, et al. Aktualisierte S3-Leitlinie Colitis ulcerosa (Version 6.2): Januar 2024 \u2013 AWMF-Registriernummer: 021\u2013009. Zeitschrift f\u00fcr Gastroenterologie. 2024;62(05):769\u2013858.","journal-title":"Zeitschrift f\u00fcr Gastroenterologie."},{"key":"4022_CR5","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A, D\u2019Amico F, Dhaliwal J, Griffiths AM, et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021;160:1570\u201383. https:\/\/doi.org\/10.1053\/j.gastro.2020.12.031.","journal-title":"Gastroenterology"},{"key":"4022_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","volume":"14","author":"J Torres","year":"2020","unstructured":"Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, et al. ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment. J Crohns Colitis. 2020;14:4\u201322. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz180.","journal-title":"J Crohns Colitis"},{"key":"4022_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","volume":"16","author":"T Raine","year":"2022","unstructured":"Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022;16:2\u201317. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab178.","journal-title":"J Crohns Colitis"},{"key":"4022_CR8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/apt.16723","volume":"55","author":"M Zhao","year":"2022","unstructured":"Zhao M, Sall Jensen M, Knudsen T, Kelsen J, Coskun M, Kjellberg J, Burisch J. Trends in the use of biologicals and their treatment outcomes among patients with inflammatory bowel diseases - a Danish nationwide cohort study. Aliment Pharmacol Ther. 2022;55:541\u201357. https:\/\/doi.org\/10.1111\/apt.16723.","journal-title":"Aliment Pharmacol Ther"},{"key":"4022_CR9","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1093\/ecco-jcc\/jjad203","volume":"18","author":"C Kapizioni","year":"2024","unstructured":"Kapizioni C, Desoki R, Lam D, Balendran K, Al-Sulais E, Subramanian S, et al. Biologic therapy for inflammatory bowel disease: real-world comparative effectiveness and impact of drug sequencing in 13 222 patients within the UK IBD BioResource. J Crohns Colitis. 2024;18:790\u2013800. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad203.","journal-title":"J Crohns Colitis"},{"key":"4022_CR10","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S2468-1253(18)30265-6","volume":"3","author":"R Atreya","year":"2018","unstructured":"Atreya R, Neurath MF. Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2018;3:790\u2013802. https:\/\/doi.org\/10.1016\/S2468-1253(18)30265-6.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4022_CR11","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1136\/gutjnl-2017-315671","volume":"68","author":"H Schmitt","year":"2019","unstructured":"Schmitt H, Billmeier U, Dieterich W, Rath T, Sonnewald S, Reid S, et al. Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn\u2019s disease. Gut. 2019;68:814\u201328. https:\/\/doi.org\/10.1136\/gutjnl-2017-315671.","journal-title":"Gut"},{"key":"4022_CR12","doi-asserted-by":"publisher","first-page":"175628482311594","DOI":"10.1177\/17562848231159452","volume":"16","author":"B Bressler","year":"2023","unstructured":"Bressler B. Is there an optimal sequence of biologic therapies for inflammatory bowel disease? Therap Adv Gastroenterol. 2023;16:17562848231159452. https:\/\/doi.org\/10.1177\/17562848231159452.","journal-title":"Therap Adv Gastroenterol"},{"key":"4022_CR13","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","volume":"142","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, van Assche G, Reinisch W, Colombel J-F, D\u2019Haens G, Wolf DC, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257-65.e1-3. https:\/\/doi.org\/10.1053\/j.gastro.2011.10.032.","journal-title":"Gastroenterology."},{"key":"4022_CR14","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel J-F, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699\u2013710. https:\/\/doi.org\/10.1056\/NEJMoa1215734.","journal-title":"N Engl J Med"},{"key":"4022_CR15","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1053\/j.gastro.2012.01.035","volume":"142","author":"P Rutgeerts","year":"2012","unstructured":"Rutgeerts P, van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel J-F, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn\u2019s disease: data from the EXTEND trial. Gastroenterology. 2012;142:1102\u20131111.e2. https:\/\/doi.org\/10.1053\/j.gastro.2012.01.035.","journal-title":"Gastroenterology"},{"key":"4022_CR16","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1053\/j.gastro.2019.06.038","volume":"157","author":"S Danese","year":"2019","unstructured":"Danese S, Sandborn WJ, Colombel J-F, Vermeire S, Glover SC, Rimola J, et al. Endoscopic, radiologic, and histologic healing with vedolizumab in patients with active Crohn\u2019s disease. Gastroenterology. 2019;157:1007\u20131018.e7. https:\/\/doi.org\/10.1053\/j.gastro.2019.06.038.","journal-title":"Gastroenterology"},{"key":"4022_CR17","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1093\/ecco-jcc\/jjab058","volume":"15","author":"B Bressler","year":"2021","unstructured":"Bressler B, Yarur A, Silverberg MS, Bassel M, Bellaguarda E, Fourment C, et al. Vedolizumab and anti-tumour necrosis factor \u03b1 real-world outcomes in biologic-na\u00efve inflammatory bowel disease patients: results from the EVOLVE study. J Crohns Colitis. 2021;15:1694\u2013706. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab058.","journal-title":"J Crohns Colitis"},{"key":"4022_CR18","doi-asserted-by":"publisher","first-page":"175628482412583","DOI":"10.1177\/17562848241258372","volume":"17","author":"B Gros","year":"2024","unstructured":"Gros B, Ross H, Nwabueze M, Constantine-Cooke N, Derikx LAAP, Lyons M, et al. Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis. Therap Adv Gastroenterol. 2024;17:17562848241258372. https:\/\/doi.org\/10.1177\/17562848241258372.","journal-title":"Therap Adv Gastroenterol"},{"key":"4022_CR19","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1053\/j.gastro.2019.05.067","volume":"157","author":"M L\u00f6wenberg","year":"2019","unstructured":"L\u00f6wenberg M, Vermeire S, Mostafavi N, Hoentjen F, Franchimont D, Bossuyt P, et al. Vedolizumab induces endoscopic and histologic remission in patients with Crohn\u2019s disease. Gastroenterology. 2019;157:997\u20131006.e6. https:\/\/doi.org\/10.1053\/j.gastro.2019.05.067.","journal-title":"Gastroenterology"},{"key":"4022_CR20","doi-asserted-by":"publisher","first-page":"i74","DOI":"10.1093\/ecco-jcc\/jjae190.0038","volume":"19","author":"MDG Bouguen","year":"2025","unstructured":"Bouguen MDG, Nachury M, Nancey S, Bouhnik Y, Bourreille A, Altwegg R, et al. OP38 Comparative efficacy of infliximab and vedolizumab after failure of a first anti-TNF in patients with ulcerative colitis: a double-blind randomized controlled trial (EFFICACI). J Crohn\u2019s Colitis. 2025;19:i74. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae190.0038.","journal-title":"J Crohn's Colitis."},{"key":"4022_CR21","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/ueg2.12563","volume":"12","author":"E Louis","year":"2024","unstructured":"Louis E, Litkiewicz M, Agboton C, Armuzzi A. Therapeutic sequencing in inflammatory bowel disease: Determining the optimal position of vedolizumab for long-term Crohn\u2019s disease control using real-world evidence. United European Gastroenterol J. 2024;12:574\u201384. https:\/\/doi.org\/10.1002\/ueg2.12563.","journal-title":"United European Gastroenterol J"},{"key":"4022_CR22","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Peyrin-Biroulet L, Loftus EV, Danese S, Colombel J-F, T\u00f6r\u00fcner M, et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 2019;381:1215\u201326. https:\/\/doi.org\/10.1056\/NEJMoa1905725.","journal-title":"N Engl J Med"},{"key":"4022_CR23","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1093\/ibd\/izab257","volume":"28","author":"A Moens","year":"2022","unstructured":"Moens A, Verstockt B, Alsoud D, Sabino J, Ferrante M, Vermeire S. Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as First-line Biological in Moderate to Severe IBD. Inflamm Bowel Dis. 2022;28:1135\u201342. https:\/\/doi.org\/10.1093\/ibd\/izab257.","journal-title":"Inflamm Bowel Dis"},{"key":"4022_CR24","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/apt.17616","volume":"58","author":"B Bokemeyer","year":"2023","unstructured":"Bokemeyer B, Plachta-Danielzik S, Di Giuseppe R, Efken P, Mohl W, Krause T, et al. Real-world effectiveness of vedolizumab compared to anti-TNF agents in biologic-na\u00efve patients with ulcerative colitis: A two-year propensity-score-adjusted analysis from the prospective, observational VEDOIBD -study. Aliment Pharmacol Ther. 2023;58:429\u201342. https:\/\/doi.org\/10.1111\/apt.17616.","journal-title":"Aliment Pharmacol Ther"},{"key":"4022_CR25","doi-asserted-by":"publisher","first-page":"adv00309","DOI":"10.2340\/00015555-3655","volume":"100","author":"S St\u00e4nder","year":"2020","unstructured":"St\u00e4nder S, Ketz M, Kossack N, Akumo D, Pignot M, Gabriel S, Chavda R. Epidemiology of prurigo nodularis compared with psoriasis in Germany: a claims database analysis. Acta Derm Venereol. 2020;100:adv00309. https:\/\/doi.org\/10.2340\/00015555-3655.","journal-title":"Acta Derm Venereol."},{"key":"4022_CR26","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1093\/ibd\/izab330","volume":"28","author":"B Bokemeyer","year":"2022","unstructured":"Bokemeyer B, Picker N, Wilke T, Rosin L, Patel H. Inadequate response, treatment patterns, health care utilization, and associated costs in patients with ulcerative colitis: retrospective cohort study based on german claims data. Inflamm Bowel Dis. 2022;28:1647\u201357. https:\/\/doi.org\/10.1093\/ibd\/izab330.","journal-title":"Inflamm Bowel Dis"},{"key":"4022_CR27","doi-asserted-by":"publisher","first-page":"274","DOI":"10.4103\/0974-7788.76794","volume":"1","author":"MK Goel","year":"2010","unstructured":"Goel MK, Khanna P, Kishore J. Understanding survival analysis: Kaplan-Meier estimate. Int J Ayurveda Res. 2010;1:274\u20138. https:\/\/doi.org\/10.4103\/0974-7788.76794.","journal-title":"Int J Ayurveda Res"},{"key":"4022_CR28","unstructured":"Diez DM. Survival Analysis in R. 2013. https:\/\/folk.ntnu.no\/bo\/TMA4275\/Download\/R.tutorialDiez.pdf. Accessed 14 Aug 2023."},{"key":"4022_CR29","unstructured":"Public statement on Remicade (infliximab) - Reports of tuberculosis infections | European Medicines Agency. 28\/03\/2024. https:\/\/www.ema.europa.eu\/en\/news\/public-statement-remicade-infliximab-reports-tuberculosis-infections. Accessed 28 Mar 2024."},{"key":"4022_CR30","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46:399\u2013424. https:\/\/doi.org\/10.1080\/00273171.2011.568786.","journal-title":"Multivariate Behav Res"},{"key":"4022_CR31","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/biomet\/87.3.706","volume":"87","author":"G Imbens","year":"2000","unstructured":"Imbens G. The role of the propensity score in estimating dose-response functions. Biometrika. 2000;87:706\u201310. https:\/\/doi.org\/10.1093\/biomet\/87.3.706.","journal-title":"Biometrika"},{"key":"4022_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s11553-022-00997-3","author":"T Wilke","year":"2022","unstructured":"Wilke T, M\u00fcller S, Ghiani M, Maywald U. Methodik und Interpretation retrospektiver vergleichender Krankenkassendatenstudien: Analyse von Patientendaten in einem Fallbeispiel (Teil 2). Pr\u00e4v Gesundheitsf. 2022. https:\/\/doi.org\/10.1007\/s11553-022-00997-3.","journal-title":"Pr\u00e4v Gesundheitsf"},{"key":"4022_CR33","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28:3083\u2013107. https:\/\/doi.org\/10.1002\/sim.3697.","journal-title":"Stat Med"},{"key":"4022_CR34","doi-asserted-by":"publisher","first-page":"otac001","DOI":"10.1093\/crocol\/otac001","volume":"4","author":"L Huynh","year":"2022","unstructured":"Huynh L, Hass S, Peyrin-Biroulet L, Duh MS, Sipsma H, Cheng M, et al. Real-world treatment patterns and physician preferences for biologics in moderate-to-severe inflammatory bowel disease: retrospective chart review in Europe. Crohns Colitis. 2022;4:otac001. https:\/\/doi.org\/10.1093\/crocol\/otac001.","journal-title":"Crohns Colitis."},{"key":"4022_CR35","doi-asserted-by":"publisher","first-page":"175628482210807","DOI":"10.1177\/17562848221080793","volume":"15","author":"A Pudipeddi","year":"2022","unstructured":"Pudipeddi A, Ko Y, Paramsothy S, Leong RW. Vedolizumab has longer persistence than infliximab as a first-line biological agent but not as a second-line biological agent in moderate-to-severe ulcerative colitis: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study. Therap Adv Gastroenterol. 2022;15:17562848221080792. https:\/\/doi.org\/10.1177\/17562848221080793.","journal-title":"Therap Adv Gastroenterol"},{"key":"4022_CR36","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1080\/03007995.2023.2194782","volume":"39","author":"JO Lindsay","year":"2023","unstructured":"Lindsay JO, Picker N, Kromer D, Smyth M, Patel H. The incidence of remission and indicators of inadequate response to advanced therapy in patients with ulcerative colitis: results from medical charts in the United Kingdom. Curr Med Res Opin. 2023;39:681\u20139. https:\/\/doi.org\/10.1080\/03007995.2023.2194782.","journal-title":"Curr Med Res Opin"},{"key":"4022_CR37","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/nejmoa0904492","volume":"362","author":"JF Colombel","year":"2010","unstructured":"Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease. N Engl J Med. 2010;362:1383\u201395. https:\/\/doi.org\/10.1056\/nejmoa0904492.","journal-title":"N Engl J Med"},{"key":"4022_CR38","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","volume":"146","author":"R Panaccione","year":"2014","unstructured":"Panaccione R, Ghosh S, Middleton S, M\u00e1rquez JR, Scott BB, Flint L, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146:392\u2013400.e3. https:\/\/doi.org\/10.1053\/j.gastro.2013.10.052.","journal-title":"Gastroenterology"},{"key":"4022_CR39","doi-asserted-by":"publisher","first-page":"612","DOI":"10.20524\/aog.2021.0645","volume":"34","author":"JG Hashash","year":"2021","unstructured":"Hashash JG, Fadel CGA, Rimmani HH, Sharara AI. Biologic monotherapy versus combination therapy with immunomodulators in the induction and maintenance of remission of Crohn\u2019s disease and ulcerative colitis. Ann Gastroenterol. 2021;34:612\u201324. https:\/\/doi.org\/10.20524\/aog.2021.0645.","journal-title":"Ann Gastroenterol"},{"key":"4022_CR40","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/s0140-6736(05)66461-6","volume":"365","author":"KF Schulz","year":"2005","unstructured":"Schulz KF, Grimes DA. Multiplicity in randomised trials I: endpoints and treatments. Lancet. 2005;365:1591\u20135. https:\/\/doi.org\/10.1016\/s0140-6736(05)66461-6.","journal-title":"Lancet"},{"key":"4022_CR41","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s10198-015-0691-z","volume":"17","author":"L Sundmacher","year":"2016","unstructured":"Sundmacher L, Ozegowski S. Regional distribution of physicians: the role of comprehensive private health insurance in Germany. Eur J Health Econ. 2016;17:443\u201351. https:\/\/doi.org\/10.1007\/s10198-015-0691-z.","journal-title":"Eur J Health Econ"},{"key":"4022_CR42","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s00103-013-1912-1","volume":"57","author":"C Ohlmeier","year":"2014","unstructured":"Ohlmeier C, Frick J, Pr\u00fctz F, Lampert T, Ziese T, Mikolajczyk R, Garbe E. Nutzungsm\u00f6glichkeiten von Routinedaten der Gesetzlichen Krankenversicherung in der Gesundheitsberichterstattung des Bundes. [Use of routine data from statutory health insurances for federal health monitoring purposes]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014;57:464\u201372. https:\/\/doi.org\/10.1007\/s00103-013-1912-1.","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz."}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04022-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04022-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04022-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T07:31:24Z","timestamp":1749195084000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-04022-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4022"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04022-7","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"assertion":[{"value":"20 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Niels Teich reports personal fees from AbbVie, Falk, Fering, Pfizer, Galapagos and Takeda outside the submitted work. Axel Dignass reports fees for participation in clinical trials, review activities such as data monitoring boards, statistical analysis and end point committees from Abivax, AbbVie, Arena Pharmaceuticals, Bristol Myers Squibb\/Celgene, Dr Falk Foundation, Galapagos, Gilead, Janssen, and Pfizer; consultancy fees from AbbVie, Amgen, Arena Pharmaceuticals, Biogen, Boehringer Ingelheim, Bristol Myers Squibb\/Celgene, Celltrion, Dr Falk Foundation, Ferring Pharmaceuticals, Fresenius Kabi, Galapagos, Janssen, Lilly, MSD, Pfizer, Pharmacosmos, Roche\/Genentech, Sandoz\/Hexal, Takeda, Tillotts, and Vifor Pharma; payment from lectures including service on speakers bureaus from AbbVie, Biogen, CED Service GmbH, Celltrion, Falk Foundation, Ferring, Galapagos, Gilead, High5MD, Janssen, Materia Prima, MedToday, MSD, Pfizer, Streamed-Up, Takeda, Tillotts, and Vifor Pharma; payment for manuscript prep-aration from Falk Foundation, Takeda, Thieme, and UniMed Verlag. Ines Weinhold and Julia Borchert declare that there are no conflicts of interest with regard to the research, authorship and\/or publication of this abstract. Both are employees of WIG2 GmbH. WIG2 GmbH received funding from Takeda Pharma Vertrieb GmbH & Co. KG for the conduct of the study. Juliane S\u00fcnwoldt, Christina D\u00fcnweber, Robert Kudernatsch and Stephan Kaiser are employees of Takeda Pharma Vertrieb GmbH & Co.KG. They hold no Takeda stock or stock options. This study was funded by Takeda Pharma Vertrieb GmbH & Co.KG.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"436"}}